{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:16:30Z","timestamp":1795025790244,"version":"4.10.2"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-58289-1","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T18:31:52Z","timestamp":1744223512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse"],"prefix":"10.1038","volume":"16","author":[{"given":"Ignacio","family":"Heras-Murillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7247-6794","authenticated-orcid":false,"given":"Diego","family":"Ma\u00f1anes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6801-1213","authenticated-orcid":false,"given":"Pablo","family":"Munn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Catal\u00e1-Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-391X","authenticated-orcid":false,"given":"Miguel A.","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5565-8561","authenticated-orcid":false,"given":"Stefanie K.","family":"Wculek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-3984","authenticated-orcid":false,"given":"David","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"58289_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).","journal-title":"Nat. Commun."},{"key":"58289_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"58289_CR3","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.2474","volume":"8","author":"H Dillek\u00e5s","year":"2019","unstructured":"Dillek\u00e5s, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 8, 5574\u20135576 (2019).","journal-title":"Cancer Med."},{"key":"58289_CR4","doi-asserted-by":"publisher","unstructured":"Correia, A. L. Locally sourced: site-specific immune barriers to metastasis. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-023-00836-2 (2023).","DOI":"10.1038\/s41577-023-00836-2"},{"key":"58289_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","volume":"48","author":"SC Jameson","year":"2018","unstructured":"Jameson, S. C. & Masopust, D. Understanding subset diversity in T cell memory. Immunity 48, 214\u2013226 (2018).","journal-title":"Immunity"},{"key":"58289_CR6","doi-asserted-by":"publisher","first-page":"698076","DOI":"10.3389\/fonc.2021.698076","volume":"11","author":"Y Jin","year":"2021","unstructured":"Jin, Y. et al. Prognostic impact of memory CD8(+) T cells on immunotherapy in human cancers: a systematic review and meta-analysis. Front. Oncol. 11, 698076 (2021).","journal-title":"Front. Oncol."},{"key":"58289_CR7","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pag\u00e8s","year":"2005","unstructured":"Pag\u00e8s, F. et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654\u20132666 (2005).","journal-title":"N. Engl. J. Med."},{"key":"58289_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms. Cancer Gene Ther. 28, 5\u201317 (2021).","journal-title":"Cancer Gene Ther."},{"key":"58289_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JIR.S343432","volume":"ume 15","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Tumor-infiltrating CD4+ central memory T cells correlated with favorable prognosis in oral squamous cell carcinoma. JIR ume 15, 141\u2013152 (2022).","journal-title":"JIR"},{"key":"58289_CR10","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.4049\/jimmunol.2100852","volume":"208","author":"H Zhang","year":"2022","unstructured":"Zhang, H., Zhu, Z., Modrak, S. & Little, A. Tissue-resident memory CD4+ T cells play a dominant role in the initiation of antitumor immunity. J. Immunol. 208, 2837\u20132846 (2022).","journal-title":"J. Immunol."},{"key":"58289_CR11","doi-asserted-by":"crossref","unstructured":"Nizard, M. et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat. Commun. 8, 15221 (2017).","DOI":"10.1038\/ncomms15221"},{"key":"58289_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-018-0812-9","volume":"565","author":"SL Park","year":"2019","unstructured":"Park, S. L. et al. Tissue-resident memory CD8+ T cells promote melanoma\u2013immune equilibrium in skin. Nature 565, 366\u2013371 (2019).","journal-title":"Nature"},{"key":"58289_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms16073","volume":"8","author":"M Enamorado","year":"2017","unstructured":"Enamorado, M. et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells. Nat. Commun. 8, 1\u201311 (2017).","journal-title":"Nat. Commun."},{"key":"58289_CR14","doi-asserted-by":"crossref","unstructured":"Wculek, S. K. et al. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. J Immunother Cancer. 5, 1\u201316 (2019).","DOI":"10.1186\/s40425-019-0565-5"},{"key":"58289_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1257","volume":"11","author":"VP Badovinac","year":"2005","unstructured":"Badovinac, V. P., Messingham, K. A. N., Jabbari, A., Haring, J. S. & Harty, J. T. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11, 748\u2013756 (2005).","journal-title":"Nat. Med."},{"key":"58289_CR16","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1245\/s10434-021-09709-1","volume":"28","author":"TJ Vreeland","year":"2021","unstructured":"Vreeland, T. J. et al. A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of stage III\/IV melanoma: a primary analysis. Ann. Surg. Oncol. 28, 6126\u20136137 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"58289_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2021.2015113","volume":"11","author":"M Bloemendal","year":"2022","unstructured":"Bloemendal, M. et al. Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology 11, 1\u201312 (2022).","journal-title":"OncoImmunology"},{"key":"58289_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira Da Costa, M. & Reis E Sousa, C. Dendritic cells revisited. Annu. Rev. Immunol. 39, 131\u2013166 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"58289_CR19","first-page":"2175","volume":"6","author":"PA Burch","year":"2000","unstructured":"Burch, P. A. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175\u20132182 (2000).","journal-title":"Clin. Cancer Res."},{"key":"58289_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"58289_CR21","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.4049\/jimmunol.170.6.2817","volume":"170","author":"P Kleindienst","year":"2003","unstructured":"Kleindienst, P. & Brocker, T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J. Immunol. 170, 2817\u20132823 (2003).","journal-title":"J. Immunol."},{"key":"58289_CR22","doi-asserted-by":"crossref","unstructured":"Yewdall, A. W., Drutman, S. B., Jinwala, F., Bahjat, K. S. & Bhardwaj, N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE 5, e11144 (2010).","DOI":"10.1371\/journal.pone.0011144"},{"key":"58289_CR23","doi-asserted-by":"crossref","unstructured":"Ashour, D. E. D. et al. IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction. JCI Insight 5, e135143 (2020).","DOI":"10.1172\/jci.insight.135143"},{"key":"58289_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","volume":"10","author":"ST Ferris","year":"2022","unstructured":"Ferris, S. T. et al. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol. Res. 10, 920\u2013931 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"58289_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JMM Den Haan","year":"2000","unstructured":"Den Haan, J. M. M., Lehar, S. M. & Bevan, M. J. CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192, 1685\u20131695 (2000).","journal-title":"J. Exp. Med."},{"key":"58289_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem, A. et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207, 1273\u20131281 (2010).","journal-title":"J. Exp. Med."},{"key":"58289_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris, S. T. et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature 584, 624\u2013629 (2020).","journal-title":"Nature"},{"key":"58289_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR S\u00e1nchez-Paulete","year":"2016","unstructured":"S\u00e1nchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti\u2013PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71\u201379 (2016).","journal-title":"Cancer Discov."},{"key":"58289_CR29","doi-asserted-by":"publisher","unstructured":"Teijeira, A. et al. Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.can-22-1046 (2022).","DOI":"10.1158\/0008-5472.can-22-1046"},{"key":"58289_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"58289_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.aav3942","volume":"5","author":"M Hubert","year":"2020","unstructured":"Hubert, M. et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci. Immunol. 5, 1\u201316 (2020).","journal-title":"Sci. Immunol."},{"key":"58289_CR32","first-page":"1","volume":"0","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 0, 1\u201316 (2018).","journal-title":"Cell"},{"key":"58289_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000474","volume":"8","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells. J. Immunother. Cancer 8, 1\u201313 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"58289_CR34","doi-asserted-by":"publisher","first-page":"e005141","DOI":"10.1136\/jitc-2022-005141","volume":"10","author":"JK Schwarze","year":"2022","unstructured":"Schwarze, J. K. et al. Intratumoral administration of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. J. Immunother. Cancer 10, e005141 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"58289_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell 177, 556\u2013571.e16 (2019).","journal-title":"Cell"},{"key":"58289_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood-2012-06-435644","volume":"121","author":"J Tel","year":"2013","unstructured":"Tel, J. et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121, 459\u2013467 (2013).","journal-title":"Blood"},{"key":"58289_CR37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1084\/jem.20111457","volume":"209","author":"E Segura","year":"2012","unstructured":"Segura, E. et al. Characterization of resident and migratory dendritic cells in human lymph nodes. J. Exp. Med. 209, 653\u2013660 (2012).","journal-title":"J. Exp. Med."},{"key":"58289_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity 55, 308\u2013323.e9 (2022).","journal-title":"Immunity"},{"key":"58289_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","volume":"37","author":"MK Ruhland","year":"2020","unstructured":"Ruhland, M. K. et al. Visualizing synaptic transfer of tumor antigens among dendritic cells. Cancer Cell 37, 786\u2013799.e5 (2020).","journal-title":"Cancer Cell"},{"key":"58289_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0787-6","volume":"7","author":"H Westdorp","year":"2019","unstructured":"Westdorp, H. et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J. Immunother. Cancer 7, 1\u201315 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"58289_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0580-6","volume":"7","author":"KF Bol","year":"2019","unstructured":"Bol, K. F. et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J. Immunother. Cancer 7, 1\u201313 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"58289_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45358-0","volume":"15","author":"KF Bol","year":"2024","unstructured":"Bol, K. F. et al. Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial. Nat. Commun. 15, 1632 (2024).","journal-title":"Nat. Commun."},{"key":"58289_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13720","volume":"7","author":"D Laoui","year":"2016","unstructured":"Laoui, D. et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun. 7, 1\u201317 (2016).","journal-title":"Nat. Commun."},{"key":"58289_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"58289_CR45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20092618","volume":"207","author":"LF Poulin","year":"2010","unstructured":"Poulin, L. F. et al. Characterization of human DNGR-1 + BDCA3 + leukocytes as putative equivalents of mouse CD8\u03b1 + dendritic cells. J. Exp. Med. 207, 1261\u20131271 (2010).","journal-title":"J. Exp. Med."},{"key":"58289_CR46","doi-asserted-by":"publisher","unstructured":"Brown, C. C. et al. Transcriptional basis of mouse and human dendritic cell heterogeneity article transcriptional basis of mouse and human dendritic cell heterogeneity. 846\u2013863 https:\/\/doi.org\/10.1016\/j.cell.2019.09.035.","DOI":"10.1016\/j.cell.2019.09.035"},{"key":"58289_CR47","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/cancers13071525","volume":"13","author":"FJ Cueto","year":"2021","unstructured":"Cueto, F. J. & Sancho, D. The Flt3L\/Flt3 axis in dendritic cell biology and cancer immunotherapy. Cancers 13, 1525 (2021).","journal-title":"Cancers"},{"key":"58289_CR48","doi-asserted-by":"crossref","unstructured":"Pantel, A. et al. Direct type I IFN but not MDA5\/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol. 12, e1001759 (2014).","DOI":"10.1371\/journal.pbio.1001759"},{"key":"58289_CR49","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.4049\/jimmunol.1202798","volume":"190","author":"C Yamazaki","year":"2013","unstructured":"Yamazaki, C. et al. Critical roles of a dendritic cell subset expressing a chemokine receptor, XCR1. J. Immunol. 190, 6071\u20136082 (2013).","journal-title":"J. Immunol."},{"key":"58289_CR50","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"BD Curti","year":"2021","unstructured":"Curti, B. D. & Faries, M. B. Recent advances in the treatment of melanoma. N. Engl. J. Med. 384, 2229\u20132240 (2021).","journal-title":"N. Engl. J. Med."},{"key":"58289_CR51","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450\u2013465 (2023).","journal-title":"Cancer Cell"},{"key":"58289_CR52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 605, 532\u2013538 (2022).","journal-title":"Nature"},{"key":"58289_CR53","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442\u2013459.e29 (2020).","journal-title":"Cell"},{"key":"58289_CR54","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986\u2013993 (2018).","journal-title":"Nat. Med."},{"key":"58289_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri.2015.3","volume":"16","author":"SN Mueller","year":"2016","unstructured":"Mueller, S. N. & Mackay, L. K. Tissue-resident memory T cells: Local specialists in immune defence. Nat. Rev. Immunol. 16, 79\u201389 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"58289_CR56","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann. Oncol. 25, 1536\u20131543 (2014).","journal-title":"Ann. Oncol."},{"key":"58289_CR57","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader, A. M. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39, 1594\u20131609.e12 (2021).","journal-title":"Cancer Cell"},{"key":"58289_CR58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"The Cancer Genome Atlas Research Network.","year":"2013","unstructured":"The Cancer Genome Atlas Research Network. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet"},{"key":"58289_CR59","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53, 1334\u20131347 (2021).","journal-title":"Nat. Genet."},{"key":"58289_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fgene.2019.00978","volume":"10","author":"C Torroja","year":"2019","unstructured":"Torroja, C. & Sanchez-Cabo, F. Digitaldlsorter: Deep-Learning on scRNA-Seq to Deconvolute Gene Expression Data. Front Genet 10, 978 (2019).","journal-title":"Front Genet"},{"key":"58289_CR61","doi-asserted-by":"publisher","unstructured":"Heras-Murillo, I., Ad\u00e1n-Barrientos, I., Gal\u00e1n, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-024-00859-1 (2024).","DOI":"10.1038\/s41571-024-00859-1"},{"key":"58289_CR62","doi-asserted-by":"publisher","first-page":"6592","DOI":"10.4049\/jimmunol.174.11.6592","volume":"174","author":"SH Naik","year":"2005","unstructured":"Naik, S. H. et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174, 6592\u20136597 (2005).","journal-title":"J. Immunol."},{"key":"58289_CR63","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1084\/jem.20020161","volume":"195","author":"T Iyoda","year":"2002","unstructured":"Iyoda, T. et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195, 1289\u20131302 (2002).","journal-title":"J. Exp. Med."},{"key":"58289_CR64","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382\u20131399 (2016).","journal-title":"Cancer Discov."},{"key":"58289_CR65","doi-asserted-by":"crossref","unstructured":"Mittendorf, E. A., Burgers, F., Haanen, J. & Cascone, T. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. American Society of Clinical Oncology Educational Book 189\u2013203 (2022).","DOI":"10.1200\/EDBK_349411"},{"key":"58289_CR66","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","volume":"12","author":"KF Grossmann","year":"2022","unstructured":"Grossmann, K. F. et al. Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma. Cancer Discov. 12, 644\u2013653 (2022).","journal-title":"Cancer Discov."},{"key":"58289_CR67","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","volume":"38","author":"AD Garg","year":"2017","unstructured":"Garg, A. D., Coulie, P. G., Van den Eynde, B. J. & Agostinis, P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 38, 577\u2013593 (2017).","journal-title":"Trends Immunol."},{"key":"58289_CR68","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn, E. et al. Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl. Acad. Sci. USA 115, 4749\u20134754 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58289_CR69","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","volume":"194","author":"F Djenidi","year":"2015","unstructured":"Djenidi, F. et al. CD8+CD103+ tumor\u2013infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475\u20133486 (2015).","journal-title":"J. Immunol."},{"key":"58289_CR70","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918\u20132935.e29 (2022).","journal-title":"Cell"},{"key":"58289_CR71","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05402-9","volume":"611","author":"A Ca\u00f1ellas-Socias","year":"2022","unstructured":"Ca\u00f1ellas-Socias, A. et al. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. Nature 611, 603\u2013613 (2022).","journal-title":"Nature"},{"key":"58289_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35615-5","volume":"14","author":"X Lei","year":"2023","unstructured":"Lei, X. et al. CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. Nat. Commun. 14, 217 (2023).","journal-title":"Nat. Commun."},{"key":"58289_CR73","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216.e8 (2024).","journal-title":"Cancer Cell"},{"key":"58289_CR74","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"58289_CR75","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1084\/jem.20181365","volume":"216","author":"LK Beura","year":"2019","unstructured":"Beura, L. K. et al. CD4+ resident memory T cells dominate immunosurveillance and orchestrate local recall responses. J. Exp. Med. 216, 1214\u20131229 (2019).","journal-title":"J. Exp. Med."},{"key":"58289_CR76","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"58289_CR77","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","volume":"3","author":"M Cohen","year":"2022","unstructured":"Cohen, M. et al. The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat. Cancer 3, 303\u2013317 (2022).","journal-title":"Nat. Cancer"},{"key":"58289_CR78","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"58289_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/0008-5472.CAN-12-1127","volume":"73","author":"EHJG Aarntzen","year":"2013","unstructured":"Aarntzen, E. H. J. G. et al. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell -based vaccination. Cancer Res. 73, 19\u201329 (2013).","journal-title":"Cancer Res."},{"key":"58289_CR80","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"58289_CR81","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1093\/bioinformatics\/btac213","volume":"38","author":"GJ Boggy","year":"2022","unstructured":"Boggy, G. J. et al. BFF and cellhashR: analysis tools for accurate demultiplexing of cell hashing data. Bioinformatics 38, 2791\u20132801 (2022).","journal-title":"Bioinformatics"},{"key":"58289_CR82","doi-asserted-by":"crossref","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 1\u201320 (2016).","DOI":"10.1186\/s13059-016-1070-5"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58289-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:02:09Z","timestamp":1744603329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58289-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58289"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58289-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.W. serves as a consultant for ONA therapeutics (Barcelona, Spain). D.S. has a research collaboration agreement with Inmunotek SL (Alcala de Henares). I.M. reports grant funding from Roche, BMS, Astrazeneca, Genmab, and Pharmamar and advisory roles with Roche-Genentech, Bristol-Myers Squibb, Astrazeneca, F-Star, Genmab, Third Rock Ventures, Amunix Pharmaceuticals, Alligator, Bioncotech, Boston Therapeutics, Bright Peak, Numab, Catalym, Pieris, and Pharmamar. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3369"}}